• Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®
  • Comprehensive data packages demonstrate each biosimilar matches its respective reference medicine in terms of quality, efficacy and safety
  • These regulatory submissions follow soon after two positive CHMP opinions** for Sandoz biosimilars etanercept and rituximab further reinforcing Sandoz immunology pipeline and the broader Novartis immunology portfolio
  • Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
  • Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
  • Poised for next growth phase, anticipated to begin in 2018

Boston, May 31, 2017 Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …

  • Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
  • Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
  • Poised for next growth phase, anticipated to begin in 2018

Boston, May 31, 2017 Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …